Partnering with Us

Augment your Pipeline with Novel, Optimized Lead Compounds.

Expiring patents and declining R&D pipeline productivity have left many pharmaceutical companies with the need to form partnerships to accelerate growth. We can help. Critical Outcome Technologies Inc. (COTI) understands the challenges our partners face.

We can augment the pipelines of our partners with our targeted libraries of novel, optimized lead compounds. We can also develop a new therapeutic target of interest to a pharmaceutical partner. Partners who license a COTI targeted library can benefit from an extension of patent life by 2-4 years and as a result increasing the lifetime revenue a drug generates. Learn more about our disease targets.

Our Process

COTI is committed to developing mutually beneficial relationships with our partners. As we develop and nurture partnerships, we are guided by our core values of integrity, reliability and responsiveness. The process begins with an initial meeting to develop an understanding of objectives and to share non-confidential information. If both parties agree to move forward appropriate non-disclosure agreements, letters of intent or understanding, material transfer agreements etc. will be put in place before additional discussions take place.